RT Journal Article SR Electronic T1 “Treatment patterns in the newly diagnosed COPD patients in Catalonia between 2007-2012” JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P1457 VO 44 IS Suppl 58 A1 Miriam Barrecheguren A1 Mónica Monteagudo A1 Jaume Ferrer A1 Eulalia Borrell A1 Carles Llor A1 Marc Miravitlles YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P1457.abstract AB Introduction:Initial treatment patterns in the newly diagnosed COPD patient usually don´t follow current clinical guidelines.Methods:Epidemiological study with data obtained from the Information System for Development in Research in Primary Care (SIDIAP), a population database that contains information of 5.8 million of habitants (80% of Catalonia´s population). Newly diagnosed COPD patients in 2007-2012 were identified through a diagnostic algorithm and information about the initial treatment patterns was collected.Results:During the study period, 40863 patients were diagnosed of COPD with an incidence rate of 18 cases per 10000 person/year.32606 were men(79.8%) with a mean age of 66.05 years(SD 11.49).44% had spirometric confirmation. As a first treatment, 18575 (45.5%) were prescribed inhaled corticosteroids ICs, 17626 (42.1%) were on long acting b-adrenergic agonists (LABA), 11519 (28.2%) short acting b-adrenergic agonists (SABA), 10008 (24.5%) short acting muscarinic antagonists (SAMA), 9758 (23.9%) patients were treated with long acting muscarinic antagonists (LAMA), and. 7353 patients (18%) received no treatment after diagnosis.Between 2007 and 2012 the use of bronchodilators (LAMA, LABA and LABA/LAMA) doubled (from 6% to 11.4%, 4.6% to 8.87% and from 1.06% to 3.73% respectively). There were little or no changes in the use of LABA + ICS (24.6% to 21.7%) and triple therapy (11.3% to 12%). Patients receiving no treatment decreased from 20.6% to 13.4%.Conclusions:ICs are frequently prescribed as a first treatment for newly diagnosed COPD patients. The use of bronchodilators alone has increased but still represents a small part of initial treatments.Study funded by Novartis Spain.